Rapamycin does not control hemophagocytic lymphohistiocytosis in LCMV-infected perforin-deficient mice.
Journal Article
Hemophagocytic lymphohistiocytosis (HLH) is an immunodysregulatory disorder for which more effective treatments are needed. The macrolide rapamycin has immunosuppressive properties, making it an attractive candidate for controlling the aberrant T cell activation that occurs in HLH. To investigate its therapeutic potential, we used rapamycin to treat Lymphocytic Choriomeningitis Virus (LCMV)-infected perforin-deficient (Prf1(-/-)) mice according to a well-established model of HLH. At the regimens tested, rapamycin did not improve weight loss, splenomegaly, hemophagocytosis, cytopenias, or proinflammatory cytokine production in LCMV-infected Prf1(-/-) animals. Thus, single agent rapamycin appears ineffective in treating the clinical and laboratory manifestations of LCMV-induced HLH.
Full Text
Duke Authors
Cited Authors
- Rothman, JA; Das, R; Teachey, DT; Paessler, ME; Nichols, KE
Published Date
- December 15, 2011
Published In
Volume / Issue
- 57 / 7
Start / End Page
- 1239 - 1243
PubMed ID
- 21681935
Pubmed Central ID
- 21681935
Electronic International Standard Serial Number (EISSN)
- 1545-5017
Digital Object Identifier (DOI)
- 10.1002/pbc.23226
Language
- eng
Conference Location
- United States